2023

1. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

   Frontiers in Immunology, Vol. 14

2. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

   Nature Communications, Vol. 14, Núm. 1